Table 1 Baseline investigations

A.

Hematological investigations

RBC

4,460,000/μL

WBC

3700/μL

DLC

a. Neutrophils

78%

b. Lymphocytes

20%

c. Eosinophils

1%

d. Monocytes

1%

e. Basophils

0%

Hemoglobin (Hb)

12.8 g/dl

Platelets

216,000/μL

Bleeding time

2 minutes (2–7 minutes)

Clotting time

8 minutes (5–15 minutes)

Prothrombin time

14 seconds (13–16 seconds)

INR

1.00

B.

Biochemical investigations

Random blood sugar (RBS)

4.7 mmol/L (3.8–7.8)

Sodium (Na)

140 mEq/L (135–146)

Potassium (K)

4 mEq/L (3.5–5.2)

C.

Thyroid function test

Free T4

15.9 pmol/L (10.2–28.2)

Thyroid-stimulating hormone (TSH)

2.48 microIU/L (0.46–4.68)

Free T3

4.3 pmol/L (4.26–8.1)

D.

Tumor markers

Carcinoembryonic antigen (CEA)

1.14 ng/ml (< 3 ng/ml)

Lactate dehydrogenase (LDH)

251 U/L (< 460)

Alpha-fetoprotein (AFP)

2.16 ng/ml (< 7.5)

Carbohydrate antigen-125 (CA-125)

21 U/ml (< 35.0)

Beta-HCG

2.39 μIU/ml (< 5)

Pap smear

Negative for malignant intra-epithelial lesion

E.

Renal function test

Urea

4.8 mmol/L (1.6–7.0)

Creatinine

64 mmol/L (40–110)

F.

Serology

1. HIV 1 and 2

Non-reactive

2. HBsAg

3. Anti-HCV

G.

Urine analysis (routine and microscopic examination)

Urine culture

Within normal limits

No growth after 72 hours of incubation